Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy a

Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rati

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consen

Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genet

Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and

Cantor Fitzgerald analyst Steve Seedhouse maintains Korro Bio (NASDAQ:KRRO) with a Overweight and

Raymond James analyst Steven Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Ou

Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst cons

Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and e

Clear Street analyst Bill Maughan upgrades Korro Bio (NASDAQ:KRRO) from Hold to Buy and raises th

Chardan Capital analyst Keay Nakae upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Buy and raise

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Korro Bio (NASDAQ:KRRO) from Neutral

Piper Sandler analyst Yasmeen Rahimi upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Overweight

Oppenheimer analyst Kostas Biliouris upgrades Korro Bio (NASDAQ:KRRO) from Perform to Outperform

Cantor Fitzgerald analyst Steve Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Neutral to Overwe

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ran